XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 33.59

+0.7%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: StockDoc who wrote (14108)	7/13/2000 12:13:10 AM
From: Bluegreen	Read Replies (1) of 17367

Just another example of what the future holds for cytokines and proteins expanding their market by ADJUNCT means.>>>>>>>>>>>>Dr. Lee Simon, the panel's acting chairman, said Centocor's study showed "compelling" evidence that giving patients Remicade in addition to methotrexate, a standard treatment, reduced joint damage over one year when compared to patients who received methotrexate and a placebo.<<<<<<<<<<<<<<<<< Interesting "compelling" was used instead of statistical significance. Hmmmmmmmmmmm.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next